Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device.
Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver INO-4800 directly into the skin. It may also be used to deliver a potential COVID-19 vaccine.
The small, portable, hand-held device that runs in “AA” batteries is designed to deliver the INO-4800 vaccine where it prompts the body’s immune system to drive an immune response. It is currently in the midst of a U.S. Phase I clinical trial, for which results will be available later this month. A Phase II/III efficacy trial is slated to begin this month or next.
Plymouth Meeting, Pa.-based Inovio said in a news release that its San Diego manufacturing facility has produced initial quantities of the device and displayed capabilities for scale-…